Renal Cell Carcinoma
RCC tumor shrinkage significantly and independently predicted overall survival.
Neoadjuvant sunitinib was linked to primary tumor and thrombus shrinkage, reduced blood loss during surgery, as well as improved cancer-specific survival.
Pathological stage was the only independent factor linked to kidney cancer progression.
The approach was defined as surgical resection with a wide margin or radiotherapy with a biologically effective dose of 140 Gy or greater.
In a study, patients who had the procedure had a better 5-year overall survival rate than those who did not (68% vs. 27%).
New finding may inform treatment decisions.
It is important to assess factors that may put patients at higher risk of metastatic disease, according to researchers.
Current practice of only focusing on tumor samples might adversely affect care.
The risk is particularly elevated for patients who have CKD risk factors, such as hypertension, diabetes, and older age.
Urine aquaporin-1 and perilipin-2 may have utility as biomarkers for diagnosing malignant clear cell or papillary renal cell carcinoma (RCC).
Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.
Patients with these risk factors should be followed up for the rest of their lives, according to the researchers.
In a study of 4,736 patients with metastatic renal cell carcinoma, use of the drugs was associated with a nearly 22% decreased risk of death.
In a study of post-menopausal women, the highest quartile of lycopene intake was associated with a significant 39% decreased risk of renal cell carcinoma versus the lowest quartile.
98% of the renal tumors were controlled at 9 months after treatment.
Nephron-sparing approach is associated with a 56% decreased risk of postoperative end-stage renal disease versus radical surgery.
Low serum albumin levels increase the risk of death in patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
Acute kidney injury developed in 23% of renal cell carcinoma patients receiving everolimus.
New study links statin use with a 52% improvement in 3-year disease-specific survival.
It preserves kidney function better than radical nephrectomy in patients with small- to medium-sized tumors, study finds.
Meta-analysis reveals a significantly increased risk of kidney stones only in male patients with kidney cancer.
Among surgically-treated renal cell carcinoma patients, diabetics have a 55% and 32% increased risk of cancer-specific and all-cause mortality.
Study shows that tumor flare resulting from discontinuation of sunitinib and pazopanib is associated with decreased overall survival.
Ultrasound surveillance for renal tumors should be performed on native and graft kidneys from 3 years after transplantation.
Are you more likely to perform partial rather than radical nephrectomy for tumors if robotic-assisted surgery is available?September 26, 2014
Availability of robotic-assisted surgery at a hospital was independently associated with greater use of partial nephrectomy.
Are you surprised that targeted therapeutics for metastatic renal cell carcinoma (RCC) have not improved survival?September 12, 2014
A study found that targeted therapeutic agents for treating metastatic RCC has not led to an improvement in survival rates.
Study also finds increase in overall cancer rate among African-American children and adolescents.
Other predictors include neurovascular disease, obesity, and surgical approach.
The 3-year survival rates for patients diagnosed during 2006-2007 were similar to those diagnosed during 2001-2005.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)